Oculis Eyes Three Key Milestones in 2026 as Cash Runway Extends to 2029
Event summary
- Oculis reported $268.7 million in cash, cash equivalents, and short-term investments as of December 31, 2025, up from $109.0 million a year earlier, providing a runway into 2029.
- The company secured FDA Breakthrough Therapy designation for Privosegtor in optic neuritis, part of the PIONEER registrational program targeting a $7+ billion U.S. market opportunity.
- Topline results from the DIAMOND Phase 3 trials for OCS-01 eye drops in diabetic macular edema (DME) are expected in Q2 2026, with a potential NDA submission in Q4 2026.
- Oculis initiated the PREDICT-1 trial for Licaminlimab, a precision medicine approach for dry eye disease, with topline results anticipated in Q4 2026.
The big picture
Oculis is positioning itself at the forefront of neuro-ophthalmology and ophthalmology innovation, with a strategic focus on addressing significant unmet medical needs. The company's robust cash position and upcoming clinical milestones underscore its potential to redefine standards of care in these fields. The broader industry trend towards precision medicine and neuroprotective treatments further amplifies Oculis' strategic relevance.
What we're watching
- Clinical Success
- Whether the topline results from the DIAMOND Phase 3 trials for OCS-01 will support a successful NDA submission in Q4 2026.
- Market Expansion
- The pace at which Privosegtor can capture the $7+ billion U.S. market opportunity in neuro-ophthalmology.
- Precision Medicine
- How the genotype-based approach for Licaminlimab will impact the treatment paradigm for dry eye disease.
Related topics